
About Entopsis
Entopsis is a Technology company based in Miami (United States) founded in 2011. Diagnostic devices for health monitoring are developed using specialized slides. Entopsis has raised $1.05 million across 3 funding rounds from investors including Krillion Ventures, G3 Capital Partners and Breakout Ventures. Entopsis offers products and services including NuTec, OpsisDx, and PCRopsis Oral Rinse. Its focus areas include High Tech, Nanotechnology, Nanoenabled Products and Life Science. Its legal entity is Entopsis LLC. Its competitors include BioMedomics, Maxwell Sensors and NanoCytomics; 1 of its 3 listed competitors has raised funding.
Company details
Specialized glass slides known as NUTEC were developed by the company, founded in 2011 and based in Miami, United States, to enable detection of DNA, RNA, proteins, and small molecules through colorimetric changes. Software utilizing machine learning is provided for data analysis. Operations focus on diagnostics in oncology, autoimmune conditions, and rare diseases within the health technology sector.
- Headquarters Miami, United States
- SectorsTechnology
- Website entopsis.com
- Social LinkedIn X Facebook YouTube
- Legal Name Entopsis Llc
- Total Equity Funding$1.05M (USD)
in 3 rounds
- Latest Funding Round$250K (USD), Seed
Dec 2016
- InvestorsKrillion Ventures
& 2 more
Products & Services of Entopsis
Entopsis offers a comprehensive portfolio of products and services, including NuTec, OpsisDx, and PCRopsis Oral Rinse.
Device for unbiased molecular identification in health monitoring.
Platform for detecting and distinguishing multiple analytes in samples.
Tool for simple oral sample collection and transportation for testing.
Apps and channels of Entopsis
its YouTube channel Entopsis has 9 subscribers and 4 videos.
Videos from Entopsis
The most watched videos on Entopsis's YouTube channel, Entopsis (9 subscribers). Click a video to play it here.
More on Entopsis.
Funding Insights of Entopsis
Entopsis has successfully raised a total of $1.05M across 3 strategic funding rounds. The most recent funding activity was a Seed round of $250 thousand completed in December 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.05M
- Total Rounds 3
- Last Round Seed β $250,000
- First Round $160,000
(May 2012)
- Investors Count 3
All 3 funding rounds of Entopsis with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2016 | $250,000 | Seed | β | β | β |
| Mar 2015 | $800,000 | Seed | β | Krillion Ventures | |
| May 2012 | $160,000 | Grant | β | β |
3 investors in total: 3 institutional.
Investors in Entopsis
Entopsis has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Krillion Ventures, G3 Capital Partners and Breakout Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
A venture capital fund based in Miami is operated. | 2022 | krillionventures.com | Miami, United States | |
Limited information is provided about G3 Capital Partners. | g3capitalpartners.com | |||
Early-stage science-driven companies are supported through venture capital investments. | breakoutlabs.org |
Investor details for Entopsis
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Entopsis
8 people are tracked at Entopsis (1 in leadership, 6 in board & advisors, 1 in team).
| Name | Role | Group |
|---|---|---|
George Huang | CFO | Leadership |
Peter Chang | Clinical Advisor | Board & advisors |
Davinder Grover | Clinical Advisor | Board & advisors |
Mari Heghinian | Member | Board & advisors |
Erika Arias | Member | Board & advisors |
Monica Goldberg | Clinical Advisor | Board & advisors |
Juan Ayala Haedo | Member | Board & advisors |
Ian Cheong | CoFounder | Team |
Complete people profiles for Entopsis
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Entopsis
3 dated milestones of Entopsis across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Entopsis is founded.
- Funding First funding round of $160K.
- Funding Latest funding round, Seed, of $250K.
Competitors of Entopsis
Entopsis has 3 listed competitors in our database, 1 of them funded. They include BioMedomics, Maxwell Sensors and NanoCytomics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biomedomics.com | 2006 | Durham, United States | $1.5M | 14 | Point-of-care diagnostic systems for blood-based disorders are developed. | |
| maxwellsensors.com | 1998 | Santa Fe Springs, United States | 24 | |||
| nano-cytomics.com | 2011 | Evanston, United States | Imaging-based diagnostic devices for cancer are developed. |
Detailed competitors of Entopsis
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Nanotechnology
3 companies that operate in the same segment as Entopsis (Nanotechnology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of technologies for analysis of genetic variation and function | 1993 | San Diego, California, United States | USD 28 M | USD 34.92 M | 9,630 | |
RNA interference-based therapeutics are developed for multiple disorders. | 2002 | Cambridge, Massachusetts, United States | USD 17 M | USD 3.71 B | 2,230 | |
Aerogel-based thermal insulation solutions are provided for energy conservation. | 2001 | United States | USD 198.35 M | USD 271.1 M | 554 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Entopsis
Complete news archive for Entopsis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Entopsis
Entopsis was founded in 2011 and raised its 1st funding round 1 year after it was founded.
Entopsis is headquartered in Miami, United States. It is registered at Miami, Florida, United States.
Entopsis is a funded company, having raised a total of $1.05M across 3 funding rounds to date. The company's 1st funding round was a Grant of $160K, raised on May 2012.
Specialized glass slides known as NUTEC were developed by the company, founded in 2011 and based in Miami, United States, to enable detection of DNA, RNA, proteins, and small molecules through colorimetric changes. Software utilizing machine learning is provided for data analysis. Operations focus on diagnostics in oncology, autoimmune conditions, and rare diseases within the health technology sector.
Entopsis's top competitors include BioMedomics, NanoCytomics and Maxwell Sensors.
Entopsis offers NuTec, OpsisDx, and PCRopsis Oral Rinse.
Entopsis has 3 investors. Key investors include Krillion Ventures, G3 Capital Partners, and Breakout Ventures.
Entopsis operates through Entopsis Llc.
